Lucira Health, Inc. (“Lucira Health” or “Lucira”), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that the company will participate in the Gilmartin Group Emerging Growth Company Showcase on August 31st, 2022.
Lucira’s management is scheduled to present virtually at the Inaugural Gilmartin Group Emerging Growth Company Showcase on Wednesday, August 31st, 2022, at 4:30 pm ET. A live and archived webcast of the event can be accessed through the Events and Presentations page of the Lucira website.
Those parties interested in registering for the Gilmartin Group Emerging Growth Company Showcase may do so by following this link.
About Lucira Health
Lucira is a medical technology company focused on the development and commercialization of innovative infectious disease tests to make lab-quality diagnostics more accessible. Lucira designed its test platform to provide accurate, reliable, PCR-quality test results anywhere and at any time. Beyond its already commercialized COVID-19 and COVID-19 & Flu Tests, Lucira is working on new diagnostic tests for respiratory infections and other categories including women’s health and sexually transmitted infections (STIs). For more information, visit www.lucirahealth.com.
Investor Contact
Greg Chodaczek
This email address is being protected from spambots. You need JavaScript enabled to view it.
332-895-3230
March 28, 2023 February 27, 2023 January 05, 2023 January 04, 2023 January 03, 2023 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load